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Background: In patients with obstructive jaundice, multi-organ dysfunction may develop.
Methods/Design: This trial is a prospective, open-label, randomized, and controlled study with the objective to
evaluate the effect of ursodeoxycholic acid in liver functional restoration in patients with obstructive jaundice after
endoscopic treatment. The aim of this study is to evaluate the effect of ursodeoxycholic acid in liver functional
restoration of patients with obstructive jaundice after endoscopic treatment. The hypothesis of this trial is that
patients with obstructive jaundice, in which will be administered UDCA, in the early phase after endoscopic
intervention will have better and faster functional restoration of the liver than patients in the control group.
Patients with obstructive jaundice, randomly, will be divided into two groups: (A) test group in which will be
administered ursodeoxycholic acid twenty-four hours after endoscopic procedure and will last fourteen days, and
(B) control group.
Serum-testing will include determination of bilirubin, alanine transaminase, aspartate transaminase, gama-glutamil
transpeptidase, alkaline phosphatase, albumin, and cholesterol levels. These parameters will be determined one day
prior endoscopic procedure, and on the third, fifth, seventh, tenth, twelfth and fourteenth days after endoscopic
intervention.
Discussion: This trial is a prospective, open-label, randomized, and controlled study to asses the effect of
ursodeoxycholic acid in liver functional restoration of patients with obstructive jaundice in the early phase after
endoscopic treatment.
Trial registration: ClinicalTrials.gov, NCT01688375
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The most common causes of obstructive jaundice are
choledocholithiasis, strictures of the biliary tract, chola-
ngiocarcinoma, carcinoma of pancreas, and pancreatitis.
First-line serum testing in a patient with obstructive
jaundice should include determination of bilirubin (total
and direct fractions), aspartate transaminase (AST), alanine* Correspondence: enverfekaj@hotmail.com
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reproduction in any medium, provided the ortransaminase (ALT), gama-glutamil transpeptidase, and
alkaline phosphatase levels [1].
In a prolonged obstruction, multi-organ dysfunction
including renal failure, cardiac dysfunction, pulmonary
dysfunction, poor hepatic metabolism and hemostasis
impairment may develop [2].
It is the conventional concept that the high level of
serum bilirubin may cause multisystemic damage in pa-
tients with obstructive jaundice. Current pathophysio-
logical studies on obstructive jaundice have shown that
the damage to the liver, kidney, and immune system of
the patients are closely related to endotoxemia. The keyd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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associated complications is endotoxemia of gut origin
because of intestinal barriere failure.
Biliary tract obstruction can cause damage to liver cells
and Kupffer cell function. In obstructive jaundice hyper
secretion of TNF (tumour necrosis factor) by Kupffer
cells may support the production of systemic cytokine
and be responsible for significant complications [3-5].
Patients with obstructive jaundice frequently suffer
haemodynamic and body fluid disturbances. Acute renal
failure is a relevant complication in obstructive jaundice.
The extra cellular water volume depletion and myocardial
dysfunction affects haemodynamic and renal disturbance
in patients with obstructive jaundice [6].
Experimental and clinical studies have suggested that a
period of at least four to six weeks is needed for the res-
toration of normal major synthetic and clearance func-
tions of the liver, as well as mucosal intestinal barrier
functions [7].
Even though there is a general assumption about the
increased bleeding tendency in obstructive jaundiced pa-
tients, it was demonstrated tendency for hyper coagula-
tion independent of increased prothrombin times. The
most probable cause of this effect is the increased activity
of fibrin polymers on platelet membrane [8].
It is important to emphasize that the most patients
with obstructive jaundice require appropriate endoscopic
and surgical procedures for their treatment [1].
There are a many studies, where ursodeoxycholic acid
(UDCA) was administrated in patients with cholestatic
liver diseases.
UDCA was discovered, by Hammerstein in 1902, as
the principal bile acid in the polar bear [9].
It is used for the dissolution of cholesterol-rich gall-
stones in patients with functioning gallbladders, and in
the treatment of primary biliary cirrhosis [10,11].
Mechanisms underlying the beneficial therapeutic ef-
fects of UDCA on cholestatic liver diseases include:
1) protection of injured cholangiocytes against toxic effects
of bile acids, 2) stimulation of impaired biliary secretion,
3) protection of hepatocytes against bile acid-induced
apoptosis, 4) immunomodulatory properties with reduce
immune-related liver damage [12-15].
In current literature, there are no a randomized, con-
trolled trials testing the effect of UDCA in liver func-
tional restoration of patients with obstructive jaundice
after endoscopic treatment.
Hypothesis
The hypothesis of this trial is that patients with obstruct-
ive jaundice, in which will be administered UDCA, in
the early phase after endoscopic intervention will have
better and faster functional restoration of the liver than
patients in the control group.Aim and purpose of the research
General aim
The aim of this study is to evaluate the effect of
UDCA in liver functional restoration of patients with




– To evaluate the effect of UDCA in relation to the
aetiology of obstructive jaundice.
– To assess that in which functional parameters of




This trial will be a prospective, open-label, randomized,
and controlled study. The objective will be to evaluate
the effect of ursodeoxycholic acid (UDCA) in the func-
tional restoration of the liver in patients with obstructive
jaundice in the early post-endoscopic phase.
Study design
After diagnosis, patients with obstructive jaundice will be
divided into two groups: (A) the test group in which will
be administered UDCA in the early phase after endo-
scopic treatment, and (B) control group, in which no
treatment will be applied with UDCA.
Diagnostic methods will be biochemical findings,
ultrasound examination, endoscopic retrograde cholangio
pancreatography (ERCP), CT-scan and magnetic reson-
ance cholangio pancreatography (MRCP).
Serum-testing in patients with obstructive jaundice
will include determination of bilirubin (total and direct
fractions), alanine transaminase (ALT), aspartate trans-
aminase (AST), gama-glutamil transpeptidase (GGT),
alkaline phosphatase, albumin, and cholesterol levels.
These parameters will be determined one day prior
endoscopic intervention, and on the third, fifth, seventh,
tenth, twelfth and fourteenth days after endoscopic
intervention.
Endoscope procedure that will end with the internal
derivation of bile shall be named as the internal bile
drainage.
Inclusion criteria are:
– Patients with obstructive jaundice
– Serum bilirubin level higher than 50 μmol/l
– 19+ years of age
– Written informed consent





– Women during the breastfeeding
– Suspected or proven primary liver diseases
– My family members
– Patients who are unable to understand our study
purpose
During our trial, from the study will be excluded pa-
tients who show signs of serious side effects and allergic
reactions after treatment with UDCA.UDCA administration
UDCA administration will begin twenty-four hours after
endoscopic procedure and will last fourteen days. UDCA
dose will be administered at 750 mg/day, divided into
three doses.Power of the study
A clinically relevant improvement of liver functional
tests is defined as an improvement of 70% of liver func-
tional tests in test group, and an improvement only 40%
in control group. In our study, to have an 80% chance of
detecting about a 40% difference (70% vs. 40%) between
two groups on improvement of liver functional tests at
an alpha level of 0.05, the power calculation indicates
that each of the two groups should have at least 48
patients.Data sources and search strategy
An electronic search was performed on PubMed (from 1
January 1985 to 1 February 2012). A combination of key-
words and MeSH terms where: ‘ursodeoxycholic acid’
AND ‘obstructive jaundice’, ‘obstructive jaundice’ AND
‘liver function tests’, ‘obstructive jaundice’AND ‘acute renal
failure’. I have used, also, limits: Type of article (selection
was- clinical trial, meta-analyses), Species (selection was-
human, animals), Text options (selection was- links to free
full text, abstract), Languages (English), Sex (male, female),
Age (all adult 19+ years), Field (all fields).Outcomes
The primary outcome measure in this trial is liver func-
tional restoration. The secondary outcome is assessment
liver functional parameters in which, treatment with
UDCA, will have greater impact. Follow-up measures
will be collected one day prior endoscopic intervention,
and on the third, fifth, seventh, tenth, twelfth and four-
teenth days after endoscopic intervention.Randomisation
Patients have to sign an informed consent for the involv-
ing in the trial a day before endoscopic procedure. Ran-
domisation will be performed at the time of transfer to
the endoscope room by using random number generator
at http://www.stattrek.com.Ethics
This study will be conducted in accordance with the
principles of the Declaration of Helsinki. The study
protocol has been approved by Ethics and Professional
Committee at University Clinical Centre of Kosovo. In-
formed consent will be obtained from all participants.Data collection and statistical analyses
Data including serum-test results will be collected in a
computer secured study platform. These data will be
collected continuously, for each patient, starting one day
before endoscopic procedure until the last data fourteen
days after intervention.
X2-analysis or Fisher exact test will perform to test the
differences in proportions of qualitative variables be-
tween groups. Mann Whitney U test and Kruskal Wallis
test will use for testing the difference between quantita-
tive variables when distribution is not normal and Stu-
dent t-test or ANOVA test when distribution is normal.
The level P < 0.05 will consider as the cut-off value for
significance.Discussion
In many studies, it was shown the positive effect of
UDCA administration in patient with cholestatic liver
desease.
UDCA exerts anti-apoptic effects in experimental
in vivo models as well as in vitro in primary human he-
patocytes. This anti-apoptic effect may contribute to the
alleviation of liver injury during UDCA treatment [16].
After UDCA administration in patients with non-
alcoholic fatty liver disease, the results show that UDCA
is able to reduce serum levels of hepatic enzymes, but
this effect is not related to modifications in liver fat con-
tent [17].
The study by Willot S, demonstrates the beneficial effect
of UDCA on liver function in children after successful
surgery for biliary atresia [18].
UDCA in a dose of 13–15 mg\kg\day should be con-
sidered in all patients with primary biliary cirrhosis who
have abnormal liver enzymes [19].
Long-term high-dose UDCA therapy is associated with
improvement in serum liver tests in primary sclerosing
cholangitis, but does not improve survival and was asso-
ciated with higher rates of serious adverse events [20].
Fekaj et al. BMC Surgery 2013, 13:38 Page 4 of 4
http://www.biomedcentral.com/1471-2482/13/38UDCA administration can be considered in cases of
nodular regenerative hyperplasia of the liver associated
with abnormalities of liver enzymes [21].
It seems that combined therapy with UDCA and poly-
unsaturated phosphatidylcholine could be considered in
obstetric cholestasis [22].
It was demonstrated that ciprofloxacin and UDCA
have a synergic effect on prevention of bacterial trans-
location in obstructive jaundiced patients [23].
This trial is a prospective, open-label, randomized, and
controlled study with the objective to evaluate the effect
of ursodeoxycholic acid in liver functional restoration in
patients with obstructive jaundice after endoscopic treat-
ment. The hypothesis of this trial is that patients with
obstructive jaundice, in which will be administered UDCA,
in the early phase after endoscopic intervention will have
better and faster functional restoration of the liver than
patients in the control group.
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